Cargando…

Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases

SARS-CoV-2 virus has attracted a lot of attention globally due to the autoimmune and inflammatory processes that were observed during the development of Covid-19 disease. Excessive activation of immune response and triggering of autoantibodies synthesis as well as an excessive synthesis of inflammat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sher, Emina Karahmet, Ćosović, Adnan, Džidić-Krivić, Amina, Farhat, Esma Karahmet, Pinjić, Emma, Sher, Farooq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969758/
https://www.ncbi.nlm.nih.gov/pubmed/36858313
http://dx.doi.org/10.1016/j.lfs.2023.121531
_version_ 1784897797838864384
author Sher, Emina Karahmet
Ćosović, Adnan
Džidić-Krivić, Amina
Farhat, Esma Karahmet
Pinjić, Emma
Sher, Farooq
author_facet Sher, Emina Karahmet
Ćosović, Adnan
Džidić-Krivić, Amina
Farhat, Esma Karahmet
Pinjić, Emma
Sher, Farooq
author_sort Sher, Emina Karahmet
collection PubMed
description SARS-CoV-2 virus has attracted a lot of attention globally due to the autoimmune and inflammatory processes that were observed during the development of Covid-19 disease. Excessive activation of immune response and triggering of autoantibodies synthesis as well as an excessive synthesis of inflammatory cytokines and the onset of cytokine storm has a vital role in the disease outcome and the occurring autoimmune complications. This scenario is reminiscent of infiltration of lymphocytes and monocytes in specific organs and the increased production of autoantibodies and chemoattractants noted in other inflammatory and autoimmune diseases. The main goal of this study is to investigate the complex inflammatory processes that occur in Covid-19 disease and to find similarities with other inflammatory diseases such as multiple sclerosis (MS), acute respiratory distress syndrome (ARDS), rheumatoid arthritis (RA) and Kawasaki syndrome to advance existing diagnostic and therapeutic protocols. The therapy with Interferon-gamma (IFN-γ) and the use of S1P receptor modulators showed promising results. However, there are many unknowns about these mechanisms and possible novel therapies. Therefore, the inflammation and autoimmunity triggered by Covid-19 should be further investigated to improve existing diagnostic procedures and therapeutic protocols for Covid-19.
format Online
Article
Text
id pubmed-9969758
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-99697582023-02-27 Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases Sher, Emina Karahmet Ćosović, Adnan Džidić-Krivić, Amina Farhat, Esma Karahmet Pinjić, Emma Sher, Farooq Life Sci Review Article SARS-CoV-2 virus has attracted a lot of attention globally due to the autoimmune and inflammatory processes that were observed during the development of Covid-19 disease. Excessive activation of immune response and triggering of autoantibodies synthesis as well as an excessive synthesis of inflammatory cytokines and the onset of cytokine storm has a vital role in the disease outcome and the occurring autoimmune complications. This scenario is reminiscent of infiltration of lymphocytes and monocytes in specific organs and the increased production of autoantibodies and chemoattractants noted in other inflammatory and autoimmune diseases. The main goal of this study is to investigate the complex inflammatory processes that occur in Covid-19 disease and to find similarities with other inflammatory diseases such as multiple sclerosis (MS), acute respiratory distress syndrome (ARDS), rheumatoid arthritis (RA) and Kawasaki syndrome to advance existing diagnostic and therapeutic protocols. The therapy with Interferon-gamma (IFN-γ) and the use of S1P receptor modulators showed promising results. However, there are many unknowns about these mechanisms and possible novel therapies. Therefore, the inflammation and autoimmunity triggered by Covid-19 should be further investigated to improve existing diagnostic procedures and therapeutic protocols for Covid-19. The Authors. Published by Elsevier Inc. 2023-04-15 2023-02-27 /pmc/articles/PMC9969758/ /pubmed/36858313 http://dx.doi.org/10.1016/j.lfs.2023.121531 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Sher, Emina Karahmet
Ćosović, Adnan
Džidić-Krivić, Amina
Farhat, Esma Karahmet
Pinjić, Emma
Sher, Farooq
Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases
title Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases
title_full Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases
title_fullStr Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases
title_full_unstemmed Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases
title_short Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases
title_sort covid-19 a triggering factor of autoimmune and multi-inflammatory diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969758/
https://www.ncbi.nlm.nih.gov/pubmed/36858313
http://dx.doi.org/10.1016/j.lfs.2023.121531
work_keys_str_mv AT shereminakarahmet covid19atriggeringfactorofautoimmuneandmultiinflammatorydiseases
AT cosovicadnan covid19atriggeringfactorofautoimmuneandmultiinflammatorydiseases
AT dzidickrivicamina covid19atriggeringfactorofautoimmuneandmultiinflammatorydiseases
AT farhatesmakarahmet covid19atriggeringfactorofautoimmuneandmultiinflammatorydiseases
AT pinjicemma covid19atriggeringfactorofautoimmuneandmultiinflammatorydiseases
AT sherfarooq covid19atriggeringfactorofautoimmuneandmultiinflammatorydiseases